Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.32 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.31 |
| ▸ | CDC25A | P30304 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24263859 | 0.96 | ALDH1A1 (0.35) | ALDH1A1ALDH2ALDH3A1CYP1A2CYP2D6 | |
| SCHEMBL24252206 | 0.93 | — | — | |
| SCHEMBL19170659 | 0.89 | — | — | |
| SCHEMBL23171525 | 0.89 | MAP3K5 (0.34) | CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL24270686 | 0.87 | ALDH1A1 (0.34) | ALDH1A1ALDH2ALDH3A1CYP1A2CYP2D6 | |
| SCHEMBL24496849 | 0.85 | ADRA2A (0.30) | — | |
| SCHEMBL20226537 | 0.84 | MAP3K5 (0.34) | CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL19199065 | 0.83 | TOP2A (0.37) | ALDH1A1CYP1A2CYP2C19MEN1KMT2A | |
| SCHEMBL23604976 | 0.83 | ALDH1A1 (0.32) | ALDH1A1CYP1A2CYP2D6CYP2C19MEN1 | |
| SCHEMBL24252205 | 0.83 | LMNA (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198314-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | SUTRO BIOPHARMA, INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198314-A1 | HEMIASTERLIN DERIVATIVES FOR CONJUGATION AND THERAPY | CYP17A1, HSD17B7, SHBG | ALDH1A1 1882/4885ALDH2 1616/4885ALDH3A1 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.